Paul Parren

Paul Parren leads scientific strategy at Lava Therapeutics, developing a novel class of bispecific antibodies that engage gamma-delta T cells to kill tumor cells, representing a new paradigm in bifunctional antibody design that moves beyond conventional alpha-beta T cell engagement. His extensive background in antibody engineering at Genmab, where he contributed to the development of DuoBody bispecific technology, has informed his approach to designing bispecific antibodies with optimized immune effector function. He is advancing bifunctional antibodies that bridge innate and adaptive immunity for enhanced anti-tumor responses.